ADTX
Aditxt, Inc.
Key Financials
Revenue
$3195
↓ 97.6%
Operating Income
$-19570724
↑ 29.8%
Gross Profit
$268
↑ 100.1%
Net Income
$-43101451
↓ 6.8%
EPS (Diluted)
$-1153.83
↑ 62.3%
Total Assets
$16.5M
↓ 48.6%
Shareholders' Equity
$5.6M
↑ 1029.7%
Total Liabilities
$12.6M
↓ 47.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/14/2026 | View on SEC |
| S-3 | 4/13/2026 | View on SEC |
| 8-K/A | 4/7/2026 | View on SEC |
| DEF 14A | 4/3/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 424B5 | 3/27/2026 | View on SEC |
| PRE 14A | 3/24/2026 | View on SEC |
| 8-K | 3/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ADTX |
| Company Name | Aditxt, Inc. |
| CIK | 1726711 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 909-488-0844 |